Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$10.76
+1.2%
$9.47
$4.58
$11.44
$532.21M1.61671,215 shs662,313 shs
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$9.23
+2.6%
$6.37
$1.45
$11.72
$498.43M1.661.42 million shs639,774 shs
Organogenesis stock logo
ORGO
Organogenesis
$4.26
+3.6%
$4.53
$2.61
$6.71
$521.39M1.68668,210 shs446,257 shs
Instil Bio, Inc. stock logo
TIL
Instil Bio
$19.40
+2.1%
$22.47
$10.80
$44.50
$128.26M2.07111,759 shs38,908 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
+1.22%+6.32%+12.55%+37.07%+55.27%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
+2.56%-3.65%+41.13%+123.49%-5.72%
Organogenesis stock logo
ORGO
Organogenesis
+3.65%+5.45%-13.06%-15.31%+47.40%
Instil Bio, Inc. stock logo
TIL
Instil Bio
+2.11%+1.68%+10.42%-38.78%-39.01%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$10.76
+1.2%
$9.47
$4.58
$11.44
$532.21M1.61671,215 shs662,313 shs
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$9.23
+2.6%
$6.37
$1.45
$11.72
$498.43M1.661.42 million shs639,774 shs
Organogenesis stock logo
ORGO
Organogenesis
$4.26
+3.6%
$4.53
$2.61
$6.71
$521.39M1.68668,210 shs446,257 shs
Instil Bio, Inc. stock logo
TIL
Instil Bio
$19.40
+2.1%
$22.47
$10.80
$44.50
$128.26M2.07111,759 shs38,908 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
+1.22%+6.32%+12.55%+37.07%+55.27%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
+2.56%-3.65%+41.13%+123.49%-5.72%
Organogenesis stock logo
ORGO
Organogenesis
+3.65%+5.45%-13.06%-15.31%+47.40%
Instil Bio, Inc. stock logo
TIL
Instil Bio
+2.11%+1.68%+10.42%-38.78%-39.01%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CryoPort, Inc. stock logo
CYRX
CryoPort
2.82
Moderate Buy$12.5616.69% Upside
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
2.75
Moderate Buy$18.57101.21% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.25
Hold$7.3372.14% Upside
Instil Bio, Inc. stock logo
TIL
Instil Bio
2.60
Moderate Buy$88.50356.19% Upside

Current Analyst Ratings Breakdown

Latest TIL, LXEO, ORGO, and CYRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/25/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/25/2025
Organogenesis stock logo
ORGO
Organogenesis
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/24/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
10/22/2025
Instil Bio, Inc. stock logo
TIL
Instil Bio
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/21/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$15.00 ➝ $13.00
10/15/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$30.00
10/15/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$30.00
10/14/2025
Instil Bio, Inc. stock logo
TIL
Instil Bio
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
10/8/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Organogenesis stock logo
ORGO
Organogenesis
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CryoPort, Inc. stock logo
CYRX
CryoPort
$237.88M2.26N/AN/A$7.44 per share1.45
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
N/AN/AN/AN/A$3.53 per shareN/A
Organogenesis stock logo
ORGO
Organogenesis
$429.31M1.26$0.22 per share19.70$2.09 per share2.04
Instil Bio, Inc. stock logo
TIL
Instil Bio
N/AN/AN/AN/A$25.96 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M$1.338.09N/AN/A37.21%-9.79%-5.42%11/6/2025 (Estimated)
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$98.33M-$3.26N/AN/AN/AN/A-94.65%-73.36%11/12/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.14N/AN/AN/A-1.92%-0.37%-0.20%11/6/2025 (Estimated)
Instil Bio, Inc. stock logo
TIL
Instil Bio
-$74.14M-$12.92N/AN/AN/AN/A-54.32%-33.65%11/12/2025 (Estimated)

Latest TIL, LXEO, ORGO, and CYRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2025Q3 2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$0.51N/AN/AN/AN/AN/A
11/12/2025N/A
Instil Bio, Inc. stock logo
TIL
Instil Bio
-$2.00N/AN/AN/AN/AN/A
11/6/2025Q3 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23N/AN/AN/A$41.22 millionN/A
11/6/2025Q3 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.07N/AN/AN/A$134.10 millionN/A
8/14/2025Q2 2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$0.64-$0.60+$0.04-$0.60N/AN/A
8/13/2025Q2 2025
Instil Bio, Inc. stock logo
TIL
Instil Bio
-$1.72-$3.24-$1.52-$3.24N/AN/A
8/7/2025Q2 2025
Organogenesis stock logo
ORGO
Organogenesis
-$0.01-$0.09-$0.08-$0.10$104.75 million$101.01 million
8/5/2025Q2 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.29-$0.09$2.05$41.74 million$45.45 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Instil Bio, Inc. stock logo
TIL
Instil Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CryoPort, Inc. stock logo
CYRX
CryoPort
0.39
16.24
15.47
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
N/A
4.43
4.43
Organogenesis stock logo
ORGO
Organogenesis
N/A
3.95
3.45
Instil Bio, Inc. stock logo
TIL
Instil Bio
0.64
14.97
14.97

Institutional Ownership

CompanyInstitutional Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
60.67%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Instil Bio, Inc. stock logo
TIL
Instil Bio
60.56%

Insider Ownership

CompanyInsider Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
5.30%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Instil Bio, Inc. stock logo
TIL
Instil Bio
47.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.07 million45.06 millionOptionable
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
5854.00 million51.14 millionNot Optionable
Organogenesis stock logo
ORGO
Organogenesis
950126.86 million85.00 millionOptionable
Instil Bio, Inc. stock logo
TIL
Instil Bio
4106.75 million3.57 millionNo Data

Recent News About These Companies

Instil Bio Reports Promising Phase 2 Study Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CryoPort stock logo

CryoPort NASDAQ:CYRX

$10.76 +0.13 (+1.22%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$10.85 +0.09 (+0.84%)
As of 10/24/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Lexeo Therapeutics stock logo

Lexeo Therapeutics NASDAQ:LXEO

$9.23 +0.23 (+2.56%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$9.38 +0.15 (+1.68%)
As of 10/24/2025 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.26 +0.15 (+3.65%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$4.26 0.00 (-0.12%)
As of 10/24/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Instil Bio stock logo

Instil Bio NASDAQ:TIL

$19.40 +0.40 (+2.11%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$19.16 -0.24 (-1.26%)
As of 10/24/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.